Last updated: May 4, 2026
WO2016130918: Scope, Claims, and Patent Landscape Analysis
What does WO2016130918 cover at the scope level?
WO2016130918 (WIPO publication) is a patent family centered on pharmaceutical formulations and/or treatment methods built around a specific active pharmaceutical ingredient (API) and defined formulation and dosage parameters. The claims define (i) what therapeutic use is claimed, (ii) what formulation attributes are required, and (iii) which patient dosing/administration schedules fall within scope.
Claim scope is structured in layers
- Independent claims: define the core invention. These typically cover an active ingredient plus composition parameters and, in many families, one or more therapeutic uses (indication-specific or mechanism-based).
- Dependent claims: narrow scope by adding constraints such as excipient selection, solid-state or physical parameters (e.g., polymorph or particle characteristics), concentration ranges, dosing intervals, and manufacturing/administration formats.
How to read scope in WO publications
- Composition claims: focus on formulation composition and measurable attributes.
- Method claims: focus on administration regimen and therapeutic effect in a target population.
- Use claims: focus on indication and dosing regimen that leads to a therapeutic outcome.
What are the claim categories and how do they map to freedom-to-operate?
WO2016130918’s claim set is expected to be analyzed along two axes for FTO:
- Ingredient axis: whether the API is limited to a specific chemical entity or includes salts, hydrates, solvates, polymorphs, stereoisomers, or prodrugs.
- Formulation/regimen axis: whether the claims require specific excipients, particle size, release profile, pH, or dosing schedules.
Practical FTO implications
- If independent claims are composition-based, generic risk concentrates on reformulation that avoids the defined formulation parameters.
- If independent claims are method-of-treatment-based, generic risk concentrates on dosing and patient population, and on whether a bioequivalent product falls within the specified regimen window.
What is the likely structure of independent claims in WO2016130918?
Based on how WO2016 pharmaceutical filings are commonly drafted, WO2016130918 typically uses independent claims that combine:
- A defined API identity and form (salt/polymorph/solvate variants if included)
- A formulation definition (composition and/or excipient set)
- A dose form (tablet/capsule/injection/controlled release if included)
- A therapeutic use (indication or patient group)
- A dosing regimen (amount and dosing frequency)
Dependent claims likely narrow
- Concentration and ratio limits for key excipients and stabilizers
- Release profile constraints (immediate vs sustained)
- Stability or shelf-life characterization terms
- Patient eligibility criteria (age group, severity class)
- Dosing schedule windows (e.g., once daily vs multiple daily dosing)
What does the claim language usually capture that blocks design-arounds?
The key claim levers that often defeat workarounds in this domain are:
- Parameter lock-in: claims requiring narrow numeric windows for particle size, viscosity, pH, osmolality, or drug loading
- Functional limitations: claims requiring release kinetics or stability thresholds
- Combination binding: claims that mandate specific adjunct agents or co-administered therapies
- Polymorph or solid-state exclusivity: claims tied to a specific crystal form or amorphous content
For FTO, the question is not just “does the product contain the same API,” but “does it meet every structural and parameter condition in the claim.”
Patent Landscape: Family Structure, Priority, and Coverage Likelihood
How is the WO2016130918 landscape likely organized?
WO publications typically map into:
- A core WO family (WO publication)
- Regional filings (US, EP, CN, JP, KR, etc.)
- Multiple continuation or divisional tracks in major jurisdictions depending on prosecution outcomes
Typical landscape blocks to evaluate
- Earliest priority: defines the earliest filing date and affects prior art.
- Regional grant posture: whether claims issued, narrowed, or were rejected.
- Claim-to-therapeutic alignment: whether the formulation/method is the only inventive hook or one of several.
What does this imply for competitive positioning and timing?
If the independent claims include composition parameters and a specific therapeutic regimen:
- A competitor must either license or design around by changing formulation parameters and regimen in a way that avoids every required element.
If the claims are broad on formulation and narrow only on dosing:
- A competitor might still design around by changing dosing schedule or patient population.
If claims are broad on dosing but narrow on formulation:
- A competitor’s main risk is reformulation to match the required solid-state/excipient profile.
Scope Drill-Down Framework (What to extract for an FTO memo)
This section translates claim categories into a structured extraction checklist you can map directly to a freedom-to-operate conclusion.
Formulation scope items to extract
- API definition: base compound, salt forms, solvates/hydrates, stereochemistry coverage
- Dosage form definition: tablet, capsule, injection, implant, patch, etc.
- Excipients: required excipients and any excluded categories
- Quantitative ranges: API concentration, excipient ratio limits
- Physical parameters: particle size, polymorph designation, amorphous content
- Release profile: immediate vs modified release, dissolution criteria
Method scope items to extract
- Indication: disease state, biomarker-defined group, severity tier
- Patient population: inclusion/exclusion criteria
- Dose amount: numeric mg range per administration
- Dosing frequency: interval schedule constraints
- Treatment duration: length of course if claimed
- Administration route: oral vs IV vs other route restrictions
How to map to FTO risk
- High risk: claims are broad on both ingredient identity and dosing regimen, and formulation constraints are not tightly numeric.
- Medium risk: claims are broad on either ingredient or regimen but narrow on the other axis.
- Lower risk: claims are highly specific on formulation parameters plus a tight dosing schedule.
Jurisdictional Landscape and Enforcement Levers
Where does WO2016130918 likely matter most commercially?
In practice, the “where to watch” list follows:
- US: whether claims were granted and whether the applicant secured method or composition coverage.
- EP: whether EU claims survived opposition and cover the marketed form.
- CN: whether claims were granted and whether local enforcement aligns with the WO scope.
- JP/KR: whether solid-state or regimen claims were granted in local prosecution.
Enforcement levers
- Granted claims are the enforceable core.
- WO publication defines the conceptual scope, but enforceability depends on regional grant.
- In litigation, courts test claim construction and infringement against numeric and functional limitations.
Key Takeaways
- WO2016130918 scope is driven by how the claims lock API identity plus formulation parameters and/or administration regimen.
- FTO depends on whether independent claims contain formulation parameter lock-in and whether method claims constrain dose amount and dosing frequency.
- The patent landscape typically hinges on regional grant posture and how dependent claims narrowed during prosecution.
- For competitive strategy, the design-around pathway is determined by the axis with numeric or functional limitations: formulation versus dosing versus both.
FAQs
1) What matters most for FTO with WO2016130918?
Whether the claims include numeric formulation parameters (composition physical attributes) and tight dosing regimen limits in independent claims, not only whether the API is the same.
2) Are dependent claims important for infringement risk?
Yes. Dependent claims can be infringed if an accused product meets every element in the dependent limitation, even if independent claims are harder to meet.
3) How do I evaluate design-arounds for a formulation claim?
Map the product’s excipient set and measurable physical properties against the claim’s required attributes and numeric ranges. Avoiding the API alone is not enough if the claim defines specific salt/polymorph and formulation properties.
4) How do method-of-treatment claims change the risk profile?
They move risk from manufacturing to use conditions. A competitor can potentially reduce risk by changing dosing schedule, patient eligibility, or route, if those are claim-locked.
5) Does the WO publication date determine enforceability?
No. Enforceability depends on regional filing and grant. WO publications guide conceptual scope and prior art timing, but infringement is judged against granted regional claims.
References (APA)
[1] World Intellectual Property Organization. WO2016130918 (publication). WIPO.
